Certified by Founder Lodge
CellCentric
United Kingdom - Cambridge
START UP
1 Disclosed Funding Rounds $25,000,000
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.
p300/CBP are twin (paralogue) acetyl transferases
Pfizer
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
CREAO AI | $10,000,000 | (Apr 21, 2026)
TraqCheck | $8,000,000 | (Apr 21, 2026)
Antioch | $8,500,000 | (Apr 21, 2026)
ScreenPoint Medical | $14,000,000 | (Apr 21, 2026)
Ultralight | $9,300,000 | (Apr 21, 2026)
